CN116726032B - Pharmaceutical composition for treating porcine reproductive and respiratory syndrome virus - Google Patents
Pharmaceutical composition for treating porcine reproductive and respiratory syndrome virus Download PDFInfo
- Publication number
- CN116726032B CN116726032B CN202310683265.5A CN202310683265A CN116726032B CN 116726032 B CN116726032 B CN 116726032B CN 202310683265 A CN202310683265 A CN 202310683265A CN 116726032 B CN116726032 B CN 116726032B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- respiratory syndrome
- porcine reproductive
- parts
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 title abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 32
- ZZAJQOPSWWVMBI-UHFFFAOYSA-N calycosin Chemical compound C1=C(O)C(OC)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZZAJQOPSWWVMBI-UHFFFAOYSA-N 0.000 claims abstract description 18
- ZJSJQWDXAYNLNS-UHFFFAOYSA-N (+) pinoresinol-4,4'-di-O-beta-D-glucopyranoside Natural products COC1=CC(C2C3C(C(OC3)C=3C=C(OC)C(OC4C(C(O)C(O)C(CO)O4)O)=CC=3)CO2)=CC=C1OC1OC(CO)C(O)C(O)C1O ZJSJQWDXAYNLNS-UHFFFAOYSA-N 0.000 claims abstract description 9
- ZJSJQWDXAYNLNS-FUPWJLLWSA-N (2s,3r,4s,5s,6r)-2-[4-[(3s,3ar,6s,6ar)-6-[3-methoxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-2-methoxyphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound COC1=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)CO2)=CC=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZJSJQWDXAYNLNS-FUPWJLLWSA-N 0.000 claims abstract description 9
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims description 19
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 claims description 14
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 241000282887 Suidae Species 0.000 abstract description 19
- 208000032625 disorder of ear Diseases 0.000 abstract description 11
- 238000002360 preparation method Methods 0.000 abstract description 6
- 239000003242 anti bacterial agent Substances 0.000 abstract description 3
- 229940088710 antibiotic agent Drugs 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- 210000002216 heart Anatomy 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 210000003734 kidney Anatomy 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 210000004072 lung Anatomy 0.000 abstract description 2
- 210000000952 spleen Anatomy 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 8
- 230000006996 mental state Effects 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010041349 Somnolence Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 241000205585 Aquilegia canadensis Species 0.000 description 2
- 241001061264 Astragalus Species 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 239000010231 banlangen Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 241000746375 Andrographis Species 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 240000001851 Artemisia dracunculus Species 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000037740 Coptis chinensis Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241001660870 Cyrtomium Species 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000218671 Ephedra Species 0.000 description 1
- 241000576429 Forsythia suspensa Species 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000972672 Phellodendron Species 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000006751 Platycodon Nutrition 0.000 description 1
- 244000274050 Platycodon grandiflorum Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 244000153955 Reynoutria sachalinensis Species 0.000 description 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 description 1
- 241001180876 Saposhnikovia Species 0.000 description 1
- 241000951473 Schizonepeta Species 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 208000024949 Swine Erysipelas Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- -1 but not limited to Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000027043 ear symptom Diseases 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 229930189914 platycodon Natural products 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a pharmaceutical composition for treating porcine reproductive and respiratory syndrome virus and application thereof, wherein the pharmaceutical composition contains active ingredients of calycosin and pinoresinol diglucoside. The pharmaceutical composition is environment-friendly, free of antibiotics, healthy and free of drug resistance, and can be well used for treating pigs infected with blue-ear diseases; the active ingredients of the medicine are clear, which is helpful for reducing the damage of other ingredients in the traditional Chinese medicine preparation to the liver, heart, spleen, lung and kidney of pigs.
Description
Technical Field
The invention relates to the veterinary field, in particular to a pharmaceutical composition for treating porcine reproductive and respiratory syndrome virus and application thereof.
Background
The porcine reproductive and respiratory syndrome is called blue ear disease for short, is a contagious disease characterized by causing sow reproductive dysfunction and porcine respiratory disease of each day of age, and the pathogen is porcine reproductive and respiratory syndrome virus. The disease has high transmission speed, and is an acute high-lethality epidemic disease caused by mutated high-pathogenicity porcine reproductive and respiratory syndrome virus. Clinically, pregnant sows are aborted in batches, die, premature birth and weak birth, the abortion rate of the pregnant sows reaches 30%, and the serious abortion rate can reach 70% or even 80%; the lactating sow is severely lack of milk, even no milk; the morbidity and mortality of the suckling pigs decrease along with the increase of the age of the days, and the mortality rate is 80-100% within 10 days of age; over 10 days old, 20% -80% is common; the growing-finishing pigs show respiratory tract infection symptoms, and the incidence rate of the high-induced blue-ear disease pigs reaches 50-80%, even more than 80%. Blue ear disease is one of the most serious diseases affecting the pig industry in the world today, and has spread rapidly since it was found, so far only a few countries have not been infected with this disease.
At present, the common practice for preventing and treating the porcine reproductive and respiratory syndrome is to apply a blue-ear virus vaccine to pigs and treat the blue-ear virus vaccine by using some antibiotics, but the effect is not ideal, and in the season and place where the porcine reproductive and respiratory syndrome is popular, most farmers of the pigs have a lot of forgetfulness, the serious forgetfulness rate of the pigs is more than 50%, and great losses are caused to the farmers. At present, the traditional Chinese medicine is used for preventing and treating the porcine reproductive and respiratory syndrome and becomes a new research direction.
For example, chinese patent application CN103054999B discloses a traditional Chinese medicine preparation for preventing and treating highly pathogenic porcine reproductive and respiratory syndrome and a preparation method thereof, wherein the traditional Chinese medicine preparation comprises the following raw medicinal materials in parts by weight: 35-65 parts of bupleurum; 15-25 parts of coptis chinensis; 20-40 parts of phellodendron; 22-58 parts of radix scutellariae; 5-15 parts of caulis akebiae; 5-15 parts of schizonepeta; 15-25 parts of divaricate saposhnikovia root; 45-75 parts of radix isatidis; 22-58 parts of ephedra herb; 35-65 parts of astragalus; 30-50 parts of honeysuckle; 30-40 parts of fructus forsythiae; 20-40 parts of common andrographis herb; 30-50 parts of mulberry leaves. The invention has good effect on preventing and treating the high pathogenicity porcine reproductive and respiratory syndrome.
For another example, chinese patent application CN102078419B discloses a medicine for preventing and treating porcine reproductive and respiratory syndrome, which is mainly prepared by pulverizing and uniformly mixing the following raw materials in parts by weight: 9 to 11 parts of pine needle, 1.5 to 2.5 parts of dried orange peel, 0.8 to 1.2 parts of white ginseng, 0.8 to 1.2 parts of baikal skullcap root, 0.8 to 1.2 parts of amur corktree bark, 1.5 to 2.5 parts of gardenia jasminoides ellis, 1.5 to 2.5 parts of radix isatidis, 0.2 to 0.4 part of liquorice, 1.5 to 2.5 parts of honeysuckle, 1.5 to 2.5 parts of virgate wormwood herb, 3.5 to 4.5 parts of astragalus root, 1.5 to 2.5 parts of cyrtomium rhizome, 0.8 to 1.2 parts of weeping forsythia, 1.5 to 2.5 parts of platycodon root, 0.8 to 1.2 parts of giant knotweed and 0.3 to 0.5 part of astragalus polysaccharide. The Chinese herbal medicine composition has better prevention effect on pigs without the infection of the porcine reproductive and respiratory syndrome, has good treatment effect on pigs with moderate porcine reproductive and respiratory syndrome symptoms, and also has obvious prevention and treatment effects on swine influenza, swine streptococcosis and swine erysipelas.
Although the traditional Chinese medicine has made certain progress in preventing and treating the porcine reproductive and respiratory syndrome, the traditional Chinese medicine of the prior art has the defects of complex formula and difficult control of product quality, and influences the application of the traditional Chinese medicine in the actual prevention and treatment of the porcine reproductive and respiratory syndrome. The invention obtains the effective components from the traditional Chinese medicine, and prepares the effective components into the pharmaceutical composition, thereby achieving a certain effect in the aspect of treating the porcine reproductive and respiratory syndrome.
Disclosure of Invention
The invention provides a pharmaceutical composition for treating porcine reproductive and respiratory syndrome virus and application thereof. In order to achieve the purpose of the invention, the following technical scheme is adopted:
in one aspect, the invention relates to a pharmaceutical composition for the treatment of porcine reproductive and respiratory syndrome virus, comprising the active ingredients calycosin and pinoresinol diglucoside.
In a preferred embodiment of the present invention, the weight ratio of calycosin to pinoresinol diglucoside is 1-2:1-2; preferably 1:1.8-2.2; particularly preferably 1:2. by adopting the preferable weight ratio, the effect of the pharmaceutical composition on preventing and treating porcine reproductive and respiratory syndrome virus is improved.
In a preferred embodiment of the invention, the pharmaceutical composition contains or does not contain other active ingredients.
In a preferred embodiment of the invention, the pharmaceutical composition further comprises pharmaceutically acceptable excipients.
In a preferred embodiment of the present invention, the pharmaceutically acceptable excipients include solubilizing agents including, but not limited to, tween 20, tween 80, and the like.
In a preferred embodiment of the present invention, the pharmaceutical composition is an oral liquid formulation.
The invention also relates to application of the pharmaceutical composition in virus prevention and treatment.
In a preferred embodiment of the invention, the virus is porcine reproductive and respiratory syndrome virus.
Compared with the prior art, the invention has the beneficial effects that:
(1) Environmental protection, no antibiotics, health and no drug resistance, and can be well used for treating pigs infected with blue ear diseases.
(2) The active ingredients of the medicine are clear, which is helpful for reducing the damage of other ingredients in the traditional Chinese medicine preparation to the liver, heart, spleen, lung and kidney of pigs.
Drawings
Fig. 1: photograph of fattening pigs suffering from blue ear disease.
Fig. 2: the mental states of the blank control group (left image) and the drug 1 treatment group (right image) before the experiment, and the two groups of pigs are mental depression, happy to lie and sleepy.
Fig. 3: the mental state after 7 days of the blank control group (left graph) and the drug 1 treatment group (right graph) test, the mental state of the drug 1 group is improved; the blank control group is happy to lie and sleepy.
Fig. 4: the mental state after 11 days of test is compared with the drug 1 group (left graph) and the drug 2 treatment group (right graph), and the mental state of the drug 2 group is good; the control drug group 1 was happy to lie and sleepy.
Detailed Description
The present invention will be described in detail by the following examples.
EXAMPLE 1 preparation of pharmaceutical compositions
Drug 1: 1g of calycosin, 2g of pinoresinol diglucoside and 2g of Tween 80 were dissolved in 500ml of physiological saline to form drug 1.
Drug 2: drug 2 was prepared by dissolving 1g of calycosin, 1.5g of pinoresinol diglucoside and 2g of Tween 80 in 500ml of physiological saline.
Drug 3: drug 3 was prepared by dissolving 1.5g of calycosin, 2g of pinoresinol diglucoside and 2g of Tween 80 in 500ml of physiological saline.
Control drug 1: control drug 1 was prepared by dissolving 3g of calycosin and 2g of Tween 80 in 500ml of physiological saline.
Control drug 2: control drug 2 was prepared by dissolving 3g of pinoresinol diglucoside in 500ml of physiological saline.
Example 2 evaluation test of clinical treatment effect of drug on porcine reproductive and respiratory syndrome
1.1 test animals
The average weight of the fattening pigs is 40kg at 360 heads and 106 days old, and the fattening pigs are divided into 6 groups of 60 heads each.
1.2 test sites
Certain mountain-east Taian stocking field
2 method
2.1 determination of the blue ear outbreak field prior to the trial.
Diagnosis of clinical symptoms:
the main symptoms of fattening pigs are represented by pale skin, abdominal respiration, emaciation, diarrhea, ear discoloration and other blue ear symptoms (shown in figure 1).
Serological diagnosis of blue ear disease: the positive rate of blue ear antigen is 82.2% for each group of sampled fattening pig serum.
Diagnosing the blue-ear disease oral liquid: the blue ear positive rate is 83.3 percent.
2.2 test methods
The 3 treatment groups and the 2 positive control groups were dosed with 2 kg/ton of water for 11 days with continuous drinking, 1 time a day, and the blank control groups were fed normally without dosing and were sampled before and on day 11 of the test.
Detection before test: serological test + oral fluid test (determination of blue ear outbreak field), post-test: and (5) oral liquid detection.
Serological detection method: 4-5ml of blood is taken from the anterior vena cava of each pig, and the supernatant is taken and put into a centrifuge tube, marked and inspected.
The oral liquid detection method comprises the following steps: binding cotton ropes of 1 meter on a pigsty gate, standing for 30 minutes, taking out, putting into a self-sealing bag, adding a proper amount of physiological saline, mixing uniformly, pouring into a centrifuge tube, marking, and checking.
3 test results
3.1 mental State
The mental states of the two groups of pigs were observed daily, recorded by photographing, and the results are shown in fig. 2-4.
3.2 mortality and blue ear Virus detection
The death number of the fattening pigs was recorded on test 11, and the blue-ear viruses were sampled and detected before and on test 11, respectively, and the test results are shown in the following table 1.
Table 1: mortality during the trial and results of blue ear disease oral fluid comparison before and after the trial
The test results show that the medicine provided by the invention can effectively reduce the positive rate and the death rate of the blue-ear disease, and particularly the proportion shown in the embodiment 1 can more effectively reduce the positive rate of the blue-ear disease.
The foregoing describes preferred embodiments of the present invention, but is not intended to limit the invention thereto. Modifications and variations to the embodiments disclosed herein may be made by those skilled in the art without departing from the scope and spirit of the invention.
Claims (5)
1. The application of a pharmaceutical composition in preparing medicines for treating porcine reproductive and respiratory syndrome comprises the following active ingredients of calycosin and pinoresinol diglucoside in a weight ratio of 1:1.8-2.2.
2. The use according to claim 1, wherein the weight ratio of calycosin to pinoresinol diglucoside is 1:2.
3. the use according to claim 1 or 2, the pharmaceutical composition further comprising a pharmaceutically acceptable adjuvant.
4. The use according to claim 3, wherein the pharmaceutically acceptable adjuvant comprises a solubilising agent.
5. The use according to claim 1 or 2, wherein the pharmaceutical composition is an oral liquid formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310683265.5A CN116726032B (en) | 2023-06-09 | 2023-06-09 | Pharmaceutical composition for treating porcine reproductive and respiratory syndrome virus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310683265.5A CN116726032B (en) | 2023-06-09 | 2023-06-09 | Pharmaceutical composition for treating porcine reproductive and respiratory syndrome virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116726032A CN116726032A (en) | 2023-09-12 |
| CN116726032B true CN116726032B (en) | 2023-11-17 |
Family
ID=87903905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310683265.5A Active CN116726032B (en) | 2023-06-09 | 2023-06-09 | Pharmaceutical composition for treating porcine reproductive and respiratory syndrome virus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116726032B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111568942A (en) * | 2020-05-25 | 2020-08-25 | 开封嘉骏生物科技有限公司 | Functional additive for blue-ear disease and preparation method thereof |
-
2023
- 2023-06-09 CN CN202310683265.5A patent/CN116726032B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111568942A (en) * | 2020-05-25 | 2020-08-25 | 开封嘉骏生物科技有限公司 | Functional additive for blue-ear disease and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116726032A (en) | 2023-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1201786C (en) | Traditional Chinese medicine composition for curing child's dyspepsia and cough and its preparing method | |
| CN116726032B (en) | Pharmaceutical composition for treating porcine reproductive and respiratory syndrome virus | |
| CN1679661A (en) | Medicine for treating female mazoplasia and preparation thereof | |
| CN102188494B (en) | Medicament for treating high fever of pigs with pure Chinese medicine | |
| CN101254270A (en) | External use traditional Chinese medicine preparation for curing gynecology inflammation and method of preparing the same | |
| CN106389562A (en) | Pudilan Xiaoyan granules, preparation method thereof, and product quality control method | |
| CN104189167B (en) | A kind of treat cataplasma of piglet diarrhea and preparation method thereof | |
| CN106389717A (en) | Piglet drug-resistant colibacillosis treating traditional Chinese medicine composition | |
| CN102379920B (en) | Veterinary antiviral and antifebrile drug composition | |
| CN105343229A (en) | Traditional Chinese medicinal composition for preventing and treating colibacillosis of livestock and poultry, and preparation method thereof | |
| CN1682969A (en) | Medicinal composition and its preparing method and quality control method | |
| CN107137485A (en) | It is a kind of to treat traditional Chinese medicine injection of swine fever and preparation method thereof | |
| CN112494612A (en) | Traditional Chinese medicine composition for miscarriage prevention and mothers benefiting of sows and preparation method thereof | |
| CN112057517A (en) | Traditional Chinese medicine composition for improving survival rate of weaned piglets, preparation method and feeding method | |
| CN116036180B (en) | Traditional Chinese medicine composition for inhibiting porcine reproductive and respiratory syndrome virus in vivo | |
| CN110354194A (en) | Chinese medicine composition and preparation method thereof for preventing and treating porcine mycoplasmal pneumonia | |
| CN113876853B (en) | Medicine for preventing and treating cow mastitis disease and preparation method and application thereof | |
| CN104415100A (en) | Compound traditional Chinese medicine powder for treating cow mastitis | |
| CN102698040A (en) | Medicament for treating porcine respiratory disease and preparation method of medicament | |
| CN102145138B (en) | Traditional Chinese medicinal preparation for preventing and treating bovine sthenia pyrosyndrome | |
| CN102552668A (en) | Traditional Chinese medicinal composition for treating lamb diarrhoea and preparation method thereof | |
| CN1259093C (en) | Medicine for preventing and treating nipple chap and its preparing method | |
| CN117883530A (en) | Traditional Chinese medicine composition for treating animal diarrhea and preparation method thereof | |
| CN112022934A (en) | Traditional Chinese medicine preparation for treating infectious proventriculitis of poultry and preparation method thereof | |
| CN111053861A (en) | Traditional Chinese medicine preparation for treating pig and chicken viral influenza and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |